The Wall Street Journal reports that Genomic Health has developed the Oncotype DX colon-cancer test, a genetic screen "that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease," according to the story. A validation study of the test was presented in advance of the American Society of Clinical Oncology annual meeting.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.